Jose F. Ponte

2.6k total citations · 1 hit paper
34 papers, 1.7k citations indexed

About

Jose F. Ponte is a scholar working on Oncology, Molecular Biology and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Jose F. Ponte has authored 34 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 21 papers in Oncology, 12 papers in Molecular Biology and 12 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Jose F. Ponte's work include HER2/EGFR in Cancer Research (16 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Epigenetics and DNA Methylation (5 papers). Jose F. Ponte is often cited by papers focused on HER2/EGFR in Cancer Research (16 papers), Monoclonal and Polyclonal Antibodies Research (10 papers) and Epigenetics and DNA Methylation (5 papers). Jose F. Ponte collaborates with scholars based in United States, United Kingdom and Germany. Jose F. Ponte's co-authors include Sam Thiagalingam, Kuang‐Hung Cheng, Arunthathi Thiagalingam, Nora D. Mineva, Hyunjoo Jean Lee, Hongjie Pan, Hamid M. Abdolmaleky, Panagiotis Papageorgis, Ming T. Tsuang and Rahim Shafa and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Jose F. Ponte

33 papers receiving 1.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code

2003 555 citations Sam Thiagalingam, Kuang‐Hung Cheng et al. Annals of the New York Academy of Sciences profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Jose F. Ponte United States	16	1.1k	461	275	215	180	34	1.7k
Weidong Jin China	22	972 0.9×	583 1.3×	112 0.4×	174 0.8×	318 1.8×	87	1.9k
Shiuh‐Wen Luoh United States	21	565 0.5×	538 1.2×	295 1.1×	95 0.4×	148 0.8×	39	1.3k
Todd A. Swanson United States	18	1.6k 1.5×	504 1.1×	367 1.3×	106 0.5×	236 1.3×	39	2.4k
Ron Loewenthal Israel	24	1.1k 1.0×	187 0.4×	192 0.7×	71 0.3×	63 0.3×	52	2.2k
Ningping Feng United States	23	607 0.6×	521 1.1×	222 0.8×	72 0.3×	134 0.7×	65	1.7k
Elizabeth O’Donnell United States	25	1.2k 1.1×	815 1.8×	116 0.4×	72 0.3×	73 0.4×	116	2.4k
Hennie T. Brüggenwirth Netherlands	25	1.3k 1.3×	255 0.6×	786 2.9×	54 0.3×	209 1.2×	73	2.1k
Michelle Russell United States	10	1.1k 1.0×	423 0.9×	63 0.2×	437 2.0×	324 1.8×	16	2.5k
Brian R. Rood United States	25	983 0.9×	282 0.6×	80 0.3×	63 0.3×	273 1.5×	55	1.7k
Pablo Hernáiz Driever Germany	34	1.2k 1.1×	408 0.9×	245 0.9×	229 1.1×	201 1.1×	143	3.1k

Countries citing papers authored by Jose F. Ponte

Since Specialization

Citations

This map shows the geographic impact of Jose F. Ponte's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jose F. Ponte with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jose F. Ponte more than expected).

Fields of papers citing papers by Jose F. Ponte

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jose F. Ponte. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jose F. Ponte. The network helps show where Jose F. Ponte may publish in the future.

Co-authorship network of co-authors of Jose F. Ponte

This figure shows the co-authorship network connecting the top 25 collaborators of Jose F. Ponte. A scholar is included among the top collaborators of Jose F. Ponte based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jose F. Ponte. Jose F. Ponte is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ponte, Jose F., Leanne Lanieri, Eshita Khera, et al.. (2020). Antibody Co-Administration Can Improve Systemic and Local Distribution of Antibody–Drug Conjugates to Increase In Vivo Efficacy. Molecular Cancer Therapeutics. 20(1). 203–212. 29 indexed citations

Qiu, Qifeng, Jose F. Ponte, Leanne Lanieri, et al.. (2019). Peptide-Cleavable Self-immolative Maytansinoid Antibody–Drug Conjugates Designed To Provide Improved Bystander Killing. ACS Medicinal Chemistry Letters. 10(10). 1393–1399. 18 indexed citations

Archer, Katie E., James R. Woods, Luke Harris, et al.. (2019). Synthesis of Highly Potent N-10 Amino-Linked DNA-Alkylating Indolinobenzodiazepine Antibody–Drug Conjugates (ADCs). ACS Medicinal Chemistry Letters. 10(8). 1211–1215. 9 indexed citations

Archer, Katie E., Erin K. Maloney, Olga Ab, et al.. (2019). Design, synthesis and evaluation of novel, potent DNA alkylating agents and their antibody-drug conjugates (ADCs). Bioorganic & Medicinal Chemistry Letters. 29(17). 2455–2458. 5 indexed citations

Brand, Christian, Jacob L. Houghton, Jose F. Ponte, et al.. (2018). Leveraging PET to image folate receptor α therapy of an antibody-drug conjugate. EJNMMI Research. 8(1). 87–87. 15 indexed citations

Hicks, Stuart W., Katharine C. Lai, L. Cristina Gavrilescu, et al.. (2017). The Antitumor Activity of IMGN529, a CD37-Targeting Antibody-Drug Conjugate, Is Potentiated by Rituximab in Non-Hodgkin Lymphoma Models. Neoplasia. 19(9). 661–671. 27 indexed citations

Ponte, Jose F., Olga Ab, Leanne Lanieri, et al.. (2016). Mirvetuximab Soravtansine (IMGN853), a Folate Receptor Alpha–Targeting Antibody-Drug Conjugate, Potentiates the Activity of Standard of Care Therapeutics in Ovarian Cancer Models. Neoplasia. 18(12). 775–784. 90 indexed citations

Ponte, Jose F., et al.. (2014). Abstract 4641: Development of modified dosing approaches to achieve specific pharmacokinetic (PK) objectives in the first-in-human phase I clinical trial of IMGN853, a folate receptor α-targeting antibody drug conjugate. Cancer Research. 74(19_Supplement). 4641–4641. 1 indexed citations

Singh, Rajeeva, Nathan Fishkin, Yelena Kovtun, et al.. (2013). Abstract C164: New tri-glycyl peptide linker offers advantages for maytansinoid antibody-drug conjugates (ADCs).. Molecular Cancer Therapeutics. 12(11_Supplement). C164–C164.

10.

Ponte, Jose F., Xiuxia Sun, Nicholas C. Yoder, et al.. (2013). Abstract 5677: The anti-EGFR ADC, IMGN289 displays favorable pharmacokinetic properties.. Cancer Research. 73(8_Supplement). 5677–5677. 1 indexed citations

11.

Chittenden, Thomas, Yulius Y. Setiady, Peter U. Park, et al.. (2013). Abstract 5467: IMGN289, an EGFR-targeting antibody-maytansinoid conjugate with potent activity against non-small cell lung cancer (NSCLC) regardless of dependency on EGFR pathway.. Cancer Research. 73(8_Supplement). 5467–5467. 3 indexed citations

12.

Ponte, Jose F., Paul Ponath, Michael J. Paglia, et al.. (2010). Enhancement of humoral and cellular immunity with an anti‐glucocorticoid‐induced tumour necrosis factor receptor monoclonal antibody. Immunology. 130(2). 231–242. 21 indexed citations

13.

Ponte, Jose F., et al.. (2010). Development of TRX518, an aglycosyl humanized monoclonal antibody (Mab) agonist of huGITR.. Journal of Clinical Oncology. 28(15_suppl). e13028–e13028. 16 indexed citations

14.

Ponte, Jose F., Panagiotis Papageorgis, Sait Öztürk, et al.. (2009). hBub1 negatively regulates p53 mediated early cell death upon mitotic checkpoint activation. Cancer Biology & Therapy. 8(7). 636–644. 13 indexed citations

15.

Ponte, Jose F., Panagiotis Papageorgis, Sait Öztürk, et al.. (2009). hBub1 deficiency triggers a novel p53 mediated early apoptotic checkpoint pathway in mitotic spindle damaged cells. Cancer Biology & Therapy. 8(7). 627–635. 11 indexed citations

16.

Abdolmaleky, Hamid M., Kuang‐Hung Cheng, Stephen V. Faraone, et al.. (2006). Hypomethylation of MB-COMT promoter is a major risk factor for schizophrenia and bipolar disorder. Human Molecular Genetics. 15(21). 3132–3145. 346 indexed citations

17.

Pan, Hongjie, Joseph A. Califano, Jose F. Ponte, et al.. (2005). Loss of Heterozygosity Patterns Provide Fingerprints for Genetic Heterogeneity in Multistep Cancer Progression of Tobacco Smoke–Induced Non–Small Cell Lung Cancer. Cancer Research. 65(5). 1664–1669. 44 indexed citations

18.

Cheng, Kuang‐Hung, Jose F. Ponte, & Sam Thiagalingam. (2004). Elucidation of Epigenetic Inactivation of SMAD8 in Cancer Using Targeted Expressed Gene Display. Cancer Research. 64(5). 1639–1646. 32 indexed citations

19.

Thiagalingam, Sam, Kuang‐Hung Cheng, Hyunjoo Jean Lee, et al.. (2003). Histone Deacetylases: Unique Players in Shaping the Epigenetic Histone Code. Annals of the New York Academy of Sciences. 983(1). 84–100. 555 indexed citations breakdown →

20.

Thiagalingam, Sam, et al.. (2002). Loss of heterozygosity as a predictor to map tumor suppressor genes in cancer: molecular basis of its occurrence. Current Opinion in Oncology. 14(1). 65–72. 86 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact